Astrana Health, Inc. Reports Fourth Quarter and Year End 2025 Results

Core Insights - Astrana Health, Inc. reported record financial results for the year ended December 31, 2025, with total revenue of $3,181.8 million, a 56% increase year-over-year, and adjusted EBITDA of $205.4 million, up 21% from the previous year [1][2][5] - The company anticipates approximately 24% revenue growth and 29% adjusted EBITDA growth for 2026, driven by the integration of Prospect Health [1][2] Financial Highlights for Year Ended December 31, 2025 - Adjusted EPS - diluted of $2.20 [1] - Adjusted EBITDA of $205.4 million, up from $170.4 million [1] - Total revenue of $3,181.8 million, up from $2,034.5 million [1] - Net income attributable to Astrana of $22.5 million [1] Financial Highlights for Fourth Quarter 2025 - Total revenue of $950.5 million, a 43% increase from $665.2 million [1] - Adjusted EBITDA of $52.5 million, up 50% from $35.0 million [1] - Net income attributable to Astrana of $6.0 million [1] Segment Results for Year Ended December 31, 2025 - Care Partners revenue of $3,022.6 million, up 55% from $1,949.0 million [1] - Care Delivery revenue of $250.7 million, up 83% [2] - Care Enablement revenue of $246.7 million, up 59% [2] Update on Annual Report Filing - The company plans to file a Form 12b-25 to extend the deadline for its Annual Report on Form 10-K due to a material weakness in internal control over financial reporting [1][2] Stock Repurchase Program - The Board of Directors increased the share repurchase program from $50 million to $100 million, with $35.9 million remaining available as of December 31, 2025 [1][2] 2026 Guidance - For the three months ending March 31, 2026, total revenue is expected to be between $900 million and $1,000 million, and adjusted EBITDA between $60 million and $70 million [2][5] - For the year ending December 31, 2026, total revenue guidance is between $3,800 million and $4,100 million, and adjusted EBITDA between $250 million and $280 million [2][5]